Latest news with #InvestEU
Business Wire
03-06-2025
- Health
- Business Wire
Leyden Labs Lands €20 Million EIB Investment Facilitated by HERA to Advance Pandemic Preparedness Activities
LUXEMBOURG & LEIDEN, the Netherlands--(BUSINESS WIRE)--The European Investment Bank (EIB) and Dutch clinical-stage biotechnology company Leyden Laboratories B.V. have signed a €20 million financing deal to advance development of the Company's broadly-protective antibodies to defend against seasonal and pandemic viral infections. Leyden Labs' lead program is a pan-influenza nasal spray currently in clinical development (PanFlu), which has the potential to provide first-in-class influenza protection and meaningfully reduce the burden of influenza infection, including in infection from Avian Flu (H5). The venture debt financing agreement is supported under the European Commission's InvestEU programme and specifically falls under 'HERA Invest.' This €110 million initiative from the European Health Union is meant to address biodefence, pandemic readiness and antimicrobial resistance in Europe, as a top-up to the European Union's InvestEU initiative, funded by the EU4Health programme. 'The COVID-19 pandemic taught us multiple lessons, including that we should strengthen the EU's preparedness and autonomy in key areas like bio sciences,' stated EIB Vice President Robert de Groot. 'With the support of the European Commission, the EIB backs highly innovative EU companies like Leyden Labs with venture debt, enabling them to grow and thrive in Europe. Technological innovations from companies like Leyden Labs are key for European competitiveness and the well-being of our society.' Hadja Lahbib, Commissioner for Equality, Preparedness and Crisis Management, added: 'Respiratory viruses are common and affect us all, especially the most medically vulnerable. Today's agreement reaffirms our commitment to invest in innovation to strengthen preparedness and protection against respiratory viruses. HERA Invest is a prime example of Europe at the forefront of medical advancements in response to serious threats to health.' 'We are thrilled with this endorsement of our approach and support from HERA and the European Investment Bank. This will accelerate our efforts to provide broad, universal protection against current and future viral outbreaks. We are grateful that HERA and the EIB understand the urgency and significance of investing in initiatives to ensure Europe is prepared for pandemic viruses. This concern is greater than ever given the increasing threat of an avian influenza outbreak,' said Koenraad Wiedhaup, co-founder and CEO of Leyden Labs. Leyden Labs' product candidates are nasal sprays that administer broadly protective antibodies directly to the respiratory mucosa. Leyden Lab's solutions are designed to work at the earliest moment, before the virus even reaches systemic circulation. Systemically administered vaccines primarily generate systemic protection against viruses, however, this may be a limitation that contributes to suboptimal efficacy. Airborne viruses, including influenza, do not directly enter systemic circulation, but rather, they enter the body through the nose and mouth. The Company's antibodies aim to protect against full viral families, so they keep working even when a virus mutates and evolves. This intranasal strategy also has the potential to benefit people with weakened immune systems because it does not rely on the person to be able to mount an immune response in order to be protective. The Company's novel approach has the potential to transform the way the healthcare ecosystem thinks about viral prophylaxis, while also providing an innovative solution for use both in times of seasonal outbreaks as well as pandemic emergencies. HERA's responsibility is to ensure that the EU and Member States are ready to act in the face of cross-border health threats. The €20 million proceeds of this financing will support further development of Leyden Labs' novel, non-vaccine approach to fighting respiratory viruses to contribute to European pandemic preparedness efforts. Background Information: Health Emergency Preparedness and Response (HERA). The European Commission's Health Emergency Preparedness and Response Authority (HERA) supports projects that strengthen preparedness and response capacities in the field of health. HERA was established as a direct consequence of the lessons learned from the initial management of the COVID-19 pandemic, to ensure a solid Union response to serious-cross border health threats and secure ready availability and accessibility of medical countermeasures. HERA's responsibility is to ensure that the EU and Member States are ready to act in the face of cross-border health threats, and its mandate covers both the strengthening of preparedness in advance of future emergencies and the implementation of a swift and efficient response once crisis hits. HERA Invest is a €110 million top-up to the InvestEU programme, funded by the EU4Health programme. It is implemented by the EIB and supports projects that focus on pathogens with pandemic potential, chemical, biological, radiological, nuclear threats, and antimicrobial resistance. Together with HERA, the EIB assesses whether an operation meets HERA Invest's criteria. The InvestEU programme provides the European Union with crucial long-term funding by leveraging substantial private and public funds in support of a sustainable recovery. It also helps mobilise private investment for EU policy priorities, such as the European Green Deal and the digital transition. InvestEU brings together under one roof the multitude of EU financial instruments previously available to support investment in the European Union, making funding for investment projects in Europe simpler, more efficient and more flexible. The programme consists of three components: the InvestEU Fund, the InvestEU Advisory Hub and the InvestEU Portal. The InvestEU Fund is deployed through implementing partners who will invest in projects using the EU budget guarantee of €26.2 billion. The entire budget guarantee will back the investment projects of the implementing partners, increase their risk-bearing capacity and thus mobilise at least €372 billion in additional investment. The European Investment Bank (EIB) is the long-term lending institution of the European Union, owned by its Member States. The Netherlands owns a 5,2% share of the EIB. It makes long-term finance available for sound investment in order to contribute towards EU policy goals and national priorities. More than 90% of its activity is in Europe. Over the last ten years, the EIB has made available more than €27 billion in financing for Dutch projects in various sectors, including research & development, sustainable mobility, drinking water, healthcare and SMEs. In 2024 the EIB Group, which also includes the EIB's subsidiary, the European Investment Fund (EIF), made available more than €3 billion for Dutch projects. Leyden Laboratories B.V. (Leyden Labs), founded in 2020, is a clinical-stage biotechnology company based in the Netherlands. Leyden Labs is working to free people from the threat of respiratory viruses, by leveraging its Mucosal Protection Platform to develop a portfolio of candidates aimed at providing protection against influenza, coronaviruses, and other respiratory viruses through a new class of broadly protective nasal sprays. Leyden Labs is supported by a strong syndicate of investors and ambassadors; VC investors include GV (formerly Google Ventures), Casdin Capital, F-Prime Capital, ClavystBio (a life sciences venture investor established by Temasek), Polaris Partners, Qiming Venture Partners, Invus, SoftBank Vision Fund 2, Byers Capital / Brook Byers and Bluebird Ventures. To learn more, visit CR9114, Leyden Labs' lead product candidate for the PanFlu program, is a human monoclonal antibody that protects against influenza in preclinical models. Leyden Labs holds an exclusive license from Janssen Pharmaceuticals Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop and commercialize CR9114.
Yahoo
27-05-2025
- Business
- Yahoo
TreeFrog Therapeutics Secures €30 Million From European Investment Bank (EIB) Marking a Significant Milestone in the Company's Journey to Accelerate the Field of Cell Therapy
€30 million financing with mix of dilutive and venture debt financing Funds to advance Parkinson's disease cell therapy program to the clinic and further develop their internal pipeline of cell therapies Deal benefits from guarantee under European Commission's Invest EU program BORDEAUX, France, May 27, 2025--(BUSINESS WIRE)--TreeFrog Therapeutics, a French biotech specializing in cell therapy has secured a €30 million financing from the European Investment Bank (EIB). The financing will support the advancement of their lead cell therapy program in Parkinson's Disease to the clinic. Funds will also be used to reinforce their internal pipeline in other disease areas with large unmet needs. Regenerative medicine holds immense potential to revolutionize healthcare to treat or cure some of the world's unmet needs in diseases of the major organs, such as the heart, lungs, pancreas and brain. Parkinson's disease is the second most common neurodegenerative disorder and the fastest growing with more than 10 million people worldwide suffering from the disease. Prevalence doubled in the last 25 years and is expected to double again before 2050. Current solutions treat symptoms only. The cell therapy in development at TreeFrog has the potential to be a best-in-class treatment due to its unique 3D format microtissues, developed from induced pluripotent cells (iPSC). The program is on track to be ready for a first-in-human trial in 2027. The €30 million financing will be available in 3 tranches of €10 million each, with TreeFrog benefiting from a new vehicle from the EIB, mixing dilutive financing, hence no principal repayment required for the initial two tranches and venture debt for the last tranche. The initial €10 million will be withdrawn during the second quarter of 2025. EIB's investment aligns with the InvestEU objective of fostering research, development and innovation. Ambroise Fayolle, vice-president of the EIB, said: "Regenerative medicine is a field that has growing importance as life expectancy rises and some diseases are still untreated. This EIB is keen to support young, dynamic European and French companies that focus on research, development and product innovation. Support from InvestEU is testimony of a wider European interest in TreeFrog's business model and new solutions for the health sector". Jaime Arango, Chief Finance Officer, TreeFrog Therapeutics, said: "We are delighted to receive this support from EIB which bolsters our cash visibility trajectory and enables us to bring our Parkinson's cell therapy to the clinic, while also reinforcing our internal pipeline of cell therapies in other disease areas." TreeFrog's success in attracting investment and partners to date is based on their proprietary technology platform, C-Stem™. This platform addresses some of the major challenges by producing high quality cells, efficiently, at commercial scale. C-Stem combines microfluidics and stem cell biology to mimic the natural environment for cells. The cells are encapsulated in alginate capsules seeded with iPSCs. These capsules protect the cells, allowing them to do what they do naturally – self-organise and grow. The protected cells are nurtured and nourished, expand exponentially and can be turned into any type of cell in large-scale bioreactors without damage and stress. This results in 3D microtissues that have unique benefits in terms of quality and functionality and integrate well after transplant. Background information About EIB The European Investment Bank (EIB), whose shareholders are the Member States of the European Union (EU), is the EU's long-term financing institution. Across eight major priorities, we support investments in climate action and the environment, digital transition and technological innovation, security and defense, cohesion, agriculture and the bioeconomy, social infrastructure, capital markets union, and a stronger Europe in a more peaceful and prosperous world. In 2024, the EIB Group, which also includes the European Investment Fund (EIF), signed nearly €89 billion in new financing in support of more than 900 projects in Europe and worldwide. In France, the EIB Group signed over a hundred operations in 2024 for a total amount of €12.6 billion. Nearly 60% of the EIB Group's annual financing supports projects contributing to climate change mitigation and adaptation, as well as the creation of a healthier environment. About TreeFrog Therapeutics TreeFrog Therapeutics is a French-based regenerative medicine biotech set to unlock access to cell therapies for millions of patients. TreeFrog is unique in its approach to cell therapy development, bringing together biophysicists, cell biologists and bioproduction engineers to address the challenges of the industry - producing and differentiating cells of quality at unprecedented scale, cost-effectively. To succeed in their mission of Cell Therapy for all, TreeFrog operates a business model that includes its own therapeutic programs and partnerships with leading biotech and industry players. Since 2021, the company has raised $82 million to advance a pipeline of stem cell-based therapies in regenerative medicine. View source version on Contacts Press contactsEIB Andrea Morawski, mobile: +352 691 284 349Website: - Press Office: press@ TreeFrog Therapeutics Rachel MooneyChief Communications Tel: +33 674063461
Yahoo
27-05-2025
- Business
- Yahoo
TreeFrog Therapeutics Secures €30 Million From European Investment Bank (EIB) Marking a Significant Milestone in the Company's Journey to Accelerate the Field of Cell Therapy
€30 million financing with mix of dilutive and venture debt financing Funds to advance Parkinson's disease cell therapy program to the clinic and further develop their internal pipeline of cell therapies Deal benefits from guarantee under European Commission's Invest EU program BORDEAUX, France, May 27, 2025--(BUSINESS WIRE)--TreeFrog Therapeutics, a French biotech specializing in cell therapy has secured a €30 million financing from the European Investment Bank (EIB). The financing will support the advancement of their lead cell therapy program in Parkinson's Disease to the clinic. Funds will also be used to reinforce their internal pipeline in other disease areas with large unmet needs. Regenerative medicine holds immense potential to revolutionize healthcare to treat or cure some of the world's unmet needs in diseases of the major organs, such as the heart, lungs, pancreas and brain. Parkinson's disease is the second most common neurodegenerative disorder and the fastest growing with more than 10 million people worldwide suffering from the disease. Prevalence doubled in the last 25 years and is expected to double again before 2050. Current solutions treat symptoms only. The cell therapy in development at TreeFrog has the potential to be a best-in-class treatment due to its unique 3D format microtissues, developed from induced pluripotent cells (iPSC). The program is on track to be ready for a first-in-human trial in 2027. The €30 million financing will be available in 3 tranches of €10 million each, with TreeFrog benefiting from a new vehicle from the EIB, mixing dilutive financing, hence no principal repayment required for the initial two tranches and venture debt for the last tranche. The initial €10 million will be withdrawn during the second quarter of 2025. EIB's investment aligns with the InvestEU objective of fostering research, development and innovation. Ambroise Fayolle, vice-president of the EIB, said: "Regenerative medicine is a field that has growing importance as life expectancy rises and some diseases are still untreated. This EIB is keen to support young, dynamic European and French companies that focus on research, development and product innovation. Support from InvestEU is testimony of a wider European interest in TreeFrog's business model and new solutions for the health sector". Jaime Arango, Chief Finance Officer, TreeFrog Therapeutics, said: "We are delighted to receive this support from EIB which bolsters our cash visibility trajectory and enables us to bring our Parkinson's cell therapy to the clinic, while also reinforcing our internal pipeline of cell therapies in other disease areas." TreeFrog's success in attracting investment and partners to date is based on their proprietary technology platform, C-Stem™. This platform addresses some of the major challenges by producing high quality cells, efficiently, at commercial scale. C-Stem combines microfluidics and stem cell biology to mimic the natural environment for cells. The cells are encapsulated in alginate capsules seeded with iPSCs. These capsules protect the cells, allowing them to do what they do naturally – self-organise and grow. The protected cells are nurtured and nourished, expand exponentially and can be turned into any type of cell in large-scale bioreactors without damage and stress. This results in 3D microtissues that have unique benefits in terms of quality and functionality and integrate well after transplant. Background information About EIB The European Investment Bank (EIB), whose shareholders are the Member States of the European Union (EU), is the EU's long-term financing institution. Across eight major priorities, we support investments in climate action and the environment, digital transition and technological innovation, security and defense, cohesion, agriculture and the bioeconomy, social infrastructure, capital markets union, and a stronger Europe in a more peaceful and prosperous world. In 2024, the EIB Group, which also includes the European Investment Fund (EIF), signed nearly €89 billion in new financing in support of more than 900 projects in Europe and worldwide. In France, the EIB Group signed over a hundred operations in 2024 for a total amount of €12.6 billion. Nearly 60% of the EIB Group's annual financing supports projects contributing to climate change mitigation and adaptation, as well as the creation of a healthier environment. About TreeFrog Therapeutics TreeFrog Therapeutics is a French-based regenerative medicine biotech set to unlock access to cell therapies for millions of patients. TreeFrog is unique in its approach to cell therapy development, bringing together biophysicists, cell biologists and bioproduction engineers to address the challenges of the industry - producing and differentiating cells of quality at unprecedented scale, cost-effectively. To succeed in their mission of Cell Therapy for all, TreeFrog operates a business model that includes its own therapeutic programs and partnerships with leading biotech and industry players. Since 2021, the company has raised $82 million to advance a pipeline of stem cell-based therapies in regenerative medicine. View source version on Contacts Press contactsEIB Andrea Morawski, mobile: +352 691 284 349Website: - Press Office: press@ TreeFrog Therapeutics Rachel MooneyChief Communications Tel: +33 674063461 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17-04-2025
- Business
- Yahoo
Triodos Bank secures €200m in EIF guarantees to support SMEs across Europe
The European Investment Fund (EIF) has signed new guarantee agreements withTriodos Bank to provide more than €200m ($227.2m) in financing for SMEs across the Netherlands, Belgium, Spain, and Germany. This initiative is part of the European Commission's InvestEU programme, which targets the support of social entrepreneurship, sustainability, and the cultural and creative sectors. The latest agreement expands the partnership between Triodos Bank and the EIF, which has delivered over €600m in SME funding across Europe since 2018. This collaboration has also empowered a wide range of social entrepreneurs, including E-Flight Academy, Fundació Oxígeno, and Nature Snacks, spanning diverse sectors such as healthcare, nutrition, e-mobility, the circular economy, and education. EIF chief executive Marjut Falkstedt said: 'Our relationship with Triodos Bank is a very successful one, having made available hundreds of millions in attractive financing for SMEs in sectors that are underserved by traditional bank financing. 'Triodos Bank has been instrumental in supporting the creative and cultural sectors, as well as social entrepreneurship, which are at the heart of European values. We are now building on that to also support sustainability in SMEs, which will be a key element in European independence and competitiveness going forward.' An increase to an existing capped guarantee from 2023 will allow Triodos Bank to offer an additional €89m in new loans for social entrepreneurship. Meanwhile, a new uncapped guarantee will support sustainability initiatives and the cultural and creative sectors. The sustainability segment of the uncapped guarantee is expected to provide up to €71m for SMEs' green investments. The cultural and creative portion aims to generate €43m in new lending, continuing the partnership between Triodos Bank and the EIF. Triodos Bank chief commercial officer Jacco Minnaar said: 'At Triodos Bank, we have a long track record of financing social entrepreneurship. The past agreements with the EIF have already shown that public and private partnerships can fuel the much-needed transitions towards a better and more sustainable world. 'I am particularly pleased with the introduction of the new guarantee for green investments by SMEs. It shows how our relationship with the EIF is continually developing and is focused on getting financing to where it is most needed.' "Triodos Bank secures €200m in EIF guarantees to support SMEs across Europe" was originally created and published by Leasing Life, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Reuters
20-02-2025
- Business
- Reuters
European Commission proposes InvestEU guarantee boost, draft document shows
LONDON, Feb 20 (Reuters) - The European Commission is proposing to increase the guarantee provided through InvestEU, the bloc's flagship programme to support sustainable investment, innovation and job creation, by 2.5 billion euros ($2.61 billion), a draft document seen by Reuters showed. By doing so, it hopes to mobilise an extra 25 billion euros in public and private investment. The document also laid out the Commission's plan to reduce the sustainable finance reporting burden on companies, amid concerns about the bloc's competitiveness. Among the proposed changes, the Commission suggested changing the definition of small and medium sized companies, reducing the amount of data they will need to report and changing the frequency of reporting. The proposed measures would expect to save 200 million euros for those involved in the process. ($1 = 0.9584 euros) Get a look at the day ahead in European and global markets with the Morning Bid Europe newsletter. Sign up here.
